|
CA2309679C
(en)
*
|
1997-11-17 |
2010-07-20 |
Peter Kufer |
Method of identifying binding site domains that retain the capacity of binding to an epitope
|
|
DK1037927T3
(da)
|
1997-12-08 |
2004-09-06 |
Emd Lexigen Res Ct Corp |
Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
|
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
CZ20003767A3
(cs)
*
|
1998-04-15 |
2002-01-16 |
Lexigen Pharmaceuticals Corp. |
Kompozice pro indukci imunitní odpovědi vůči zvolenému typu buňek v organismu savce a její pouľití pro výrobu léčiva
|
|
WO2000018806A1
(de)
*
|
1998-09-25 |
2000-04-06 |
Horst Lindhofer |
Bispezifische und trispezifische antikörper, die spezifisch mit induzierbaren oberflächenantigenen als operationelle zielstrukturen reagieren
|
|
ATE255420T1
(de)
*
|
1998-09-25 |
2003-12-15 |
Horst Lindhofer |
Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
|
|
CZ20014123A3
(cs)
*
|
1999-05-19 |
2002-06-12 |
Lexigen Pharmaceuticals Corp. |
Exprese a export interferonů-alfa jako Fc fúzních proteinů
|
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
RU2263118C2
(ru)
*
|
1999-08-09 |
2005-10-27 |
Лексиген Фармасьютикэлс Корп. |
Комплексы антител с несколькими цитокинами
|
|
US8048416B2
(en)
*
|
1999-10-08 |
2011-11-01 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
|
US20080124327A1
(en)
*
|
1999-10-08 |
2008-05-29 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
|
US7419792B2
(en)
*
|
1999-10-08 |
2008-09-02 |
Arius Research Inc. |
Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
|
|
US20090004103A1
(en)
*
|
1999-10-08 |
2009-01-01 |
Young David S F |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
|
US7947496B2
(en)
*
|
1999-10-08 |
2011-05-24 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
|
US20050100542A1
(en)
*
|
1999-10-08 |
2005-05-12 |
Young David S. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
|
US8071072B2
(en)
|
1999-10-08 |
2011-12-06 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
|
JP2003514552A
(ja)
|
1999-11-12 |
2003-04-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改善された性質を有するエリトロポエチンの形態
|
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
|
CA2399832C
(en)
*
|
2000-02-11 |
2011-09-20 |
Stephen D. Gillies |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
CA2412845C
(en)
*
|
2000-06-29 |
2014-07-22 |
Lexigen Pharmaceuticals Corp. |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
|
DE10043437A1
(de)
*
|
2000-09-04 |
2002-03-28 |
Horst Lindhofer |
Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
|
|
PL206701B1
(pl)
*
|
2001-03-07 |
2010-09-30 |
Merck Patent Gmbh |
Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
|
|
US6992174B2
(en)
*
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
CN1294148C
(zh)
*
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
WO2002090566A2
(en)
*
|
2001-05-03 |
2002-11-14 |
Merck Patent Gmbh |
Recombinant tumor specific antibody and use thereof
|
|
JP4214249B2
(ja)
|
2001-07-30 |
2009-01-28 |
学校法人慶應義塾 |
Ｆｃ受容体γ鎖活性化物質を含有する医薬組成物
|
|
CA2469151C
(en)
|
2001-12-04 |
2013-08-13 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Immunocytokines with modulated selectivity
|
|
PT1572748E
(pt)
*
|
2002-12-17 |
2010-09-28 |
Merck Patent Gmbh |
Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
|
|
WO2004092195A2
(en)
*
|
2003-04-09 |
2004-10-28 |
Administrators Of The Tulane Educational Fund |
Dendritic cell binding proteins and uses thereof
|
|
EP1532984A1
(en)
*
|
2003-11-19 |
2005-05-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia
|
|
AU2004309050B2
(en)
*
|
2003-12-30 |
2010-10-14 |
Merck Patent Gmbh |
IL-7 fusion proteins
|
|
DK1699821T3
(da)
*
|
2003-12-31 |
2012-07-16 |
Merck Patent Gmbh |
Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
|
|
WO2005066348A2
(en)
*
|
2004-01-05 |
2005-07-21 |
Emd Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
|
JP5080243B2
(ja)
|
2004-04-21 |
2012-11-21 |
ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド |
ポリ−Ｎ−アセチルグルコサミン（ＰＮＡＧ／ｄＰＮＡＧ）結合ペプチドおよびその使用方法
|
|
US7670595B2
(en)
*
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
US8066989B2
(en)
*
|
2004-11-30 |
2011-11-29 |
Trion Pharma Gmbh |
Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
|
|
EP1819728B1
(en)
*
|
2004-12-09 |
2010-04-21 |
MERCK PATENT GmbH |
Il-7 variants with reduced immunogenicity
|
|
WO2006114115A1
(de)
|
2005-04-26 |
2006-11-02 |
Trion Pharma Gmbh |
Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
|
|
GB0512225D0
(en)
*
|
2005-06-16 |
2005-07-27 |
Univ Sheffield |
Immunoglobulin molecules
|
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
|
CN101426521A
(zh)
*
|
2005-12-21 |
2009-05-06 |
医疗免疫有限责任公司 |
EPHA2 BiTE分子及其应用
|
|
EP1820513A1
(en)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
|
|
US7906117B2
(en)
*
|
2007-05-21 |
2011-03-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
|
SG183742A1
(en)
|
2007-05-21 |
2012-09-27 |
Alderbio Holdings Llc |
Antibodies to il-6 and use thereof
|
|
US8178101B2
(en)
|
2007-05-21 |
2012-05-15 |
Alderbio Holdings Inc. |
Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
|
|
US9701747B2
(en)
|
2007-05-21 |
2017-07-11 |
Alderbio Holdings Llc |
Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
|
|
US8252286B2
(en)
|
2007-05-21 |
2012-08-28 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
|
US8404235B2
(en)
*
|
2007-05-21 |
2013-03-26 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
|
AU2008254578B2
(en)
*
|
2007-05-21 |
2013-06-06 |
Alderbio Holdings Llc |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
|
US20090238825A1
(en)
*
|
2007-05-21 |
2009-09-24 |
Kovacevich Brian R |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
|
US8062864B2
(en)
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
|
US8323649B2
(en)
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
|
US8420089B2
(en)
|
2008-11-25 |
2013-04-16 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
|
US8992920B2
(en)
|
2008-11-25 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of arthritis
|
|
US8337847B2
(en)
|
2008-11-25 |
2012-12-25 |
Alderbio Holdings Llc |
Methods of treating anemia using anti-IL-6 antibodies
|
|
US9212223B2
(en)
|
2008-11-25 |
2015-12-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
|
US9452227B2
(en)
|
2008-11-25 |
2016-09-27 |
Alderbio Holdings Llc |
Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
|
|
BRPI1016204A2
(pt)
*
|
2009-04-22 |
2016-04-19 |
Merck Patent Gmbh |
proteínas de fusão de anticorpos com sítios de ligação fcrn modificados
|
|
WO2010151792A1
(en)
*
|
2009-06-26 |
2010-12-29 |
Regeneron Pharmaceuticals, Inc. |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
SG177560A1
(en)
*
|
2009-07-06 |
2012-03-29 |
Hoffmann La Roche |
Bi-specific digoxigenin binding antibodies
|
|
WO2011066369A2
(en)
|
2009-11-24 |
2011-06-03 |
Alder Biopharmaceuticals, Inc. |
Antagonists of il-6 to raise albumin and/or lower crp
|
|
US9775921B2
(en)
|
2009-11-24 |
2017-10-03 |
Alderbio Holdings Llc |
Subcutaneously administrable composition containing anti-IL-6 antibody
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
LT3095871T
(lt)
|
2010-02-08 |
2019-05-27 |
Regeneron Pharmaceuticals, Inc. |
Bendros lengvosios grandinės pelė
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
EP2547359B1
(en)
|
2010-03-15 |
2016-03-09 |
The Board of Trustees of the University of Illionis |
Inhibitors of beta integrin-g protein alpha subunit binding interactions
|
|
KR102117771B1
(ko)
|
2010-03-31 |
2020-06-02 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
|
JP2014500879A
(ja)
|
2010-11-16 |
2014-01-16 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
|
|
US9304134B2
(en)
|
2010-11-23 |
2016-04-05 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of anemia
|
|
WO2012087943A2
(en)
|
2010-12-20 |
2012-06-28 |
The Regents Of The University Of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
|
JP2014518615A
(ja)
|
2011-04-22 |
2014-08-07 |
エマージェント プロダクト デベロップメント シアトル， エルエルシー |
前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
|
|
EP2525222A1
(en)
|
2011-05-17 |
2012-11-21 |
Markus M. Heiss |
Initial relative lymphocyte count as predictive biomarker
|
|
EP2524699A1
(en)
|
2011-05-17 |
2012-11-21 |
Trion Research GmbH |
Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
|
|
EP2709655B1
(en)
|
2011-05-17 |
2018-11-14 |
Trion Research GmbH |
Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
|
|
EP2543680A1
(en)
*
|
2011-07-07 |
2013-01-09 |
Centre National de la Recherche Scientifique |
Multispecific mutated antibody Fab fragments
|
|
PL3572517T3
(pl)
|
2011-08-05 |
2021-10-04 |
Regeneron Pharmaceuticals, Inc. |
Myszy z humanizowanym uniwersalnym łańcuchem lekkim
|
|
EP2578230A1
(en)
|
2011-10-04 |
2013-04-10 |
Trion Pharma Gmbh |
Removal of Tumor Cells from Intraoperative Autologous Blood Salvage
|
|
PT2850106T
(pt)
*
|
2012-05-18 |
2022-07-18 |
Aptevo Res & Development Llc |
Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
IN2015MN00139A
(da)
|
2012-09-25 |
2015-10-16 |
Glenmark Pharmaceuticals Sa |
|
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
|
EP3620468A1
(en)
|
2013-02-05 |
2020-03-11 |
EngMab Sàrl |
Method for the selection of antibodies against bcma
|
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
EA036577B1
(ru)
|
2013-11-04 |
2020-11-25 |
Икнос Сайенсиз Са |
Получение переориентирующих т-клетки гетеродимерных иммуноглобулинов
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
MX2016012274A
(es)
|
2014-03-21 |
2017-05-23 |
Regeneron Pharma |
Animales no humanos que producen proteinas de union de dominio simple.
|
|
KR20220025917A
(ko)
*
|
2014-05-29 |
2022-03-03 |
마크로제닉스, 인크. |
삼중-특이적 결합 분자 및 그것의 사용 방법
|
|
AR101262A1
(es)
|
2014-07-26 |
2016-12-07 |
Regeneron Pharma |
Plataforma de purificación para anticuerpos biespecíficos
|
|
ES2850325T3
(es)
|
2014-10-09 |
2021-08-27 |
Engmab Sarl |
Anticuerpos biespecíficos contra CD3epsilon y ROR1
|
|
JP6681396B2
(ja)
|
2014-11-17 |
2020-04-15 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｃｄ３ｘｃｄ２０二特異性抗体を用いて腫瘍を治療する方法
|
|
CA2968987C
(en)
*
|
2014-12-08 |
2022-05-10 |
1Globe Biomedical Co., Ltd. |
Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
|
|
WO2016149678A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
JP6688551B2
(ja)
|
2015-05-21 |
2020-04-28 |
ハープーン セラピューティクス，インク． |
三重特異性結合タンパク質と使用方法
|
|
EA202092435A3
(ru)
|
2015-08-03 |
2021-06-30 |
Энгмаб Сарл |
Моноклональные антитела против bcma
|
|
JP7002446B2
(ja)
|
2015-09-21 |
2022-03-04 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
Ｃｄ３結合ポリペプチド
|
|
GEP20217317B
(en)
|
2015-10-08 |
2021-11-10 |
Macrogenics Inc |
Combination therapy for the treatment of cancer
|
|
RU2770006C2
(ru)
|
2016-05-16 |
2022-04-14 |
Такеда Фармасьютикал Компани Лимитед |
Антитела к фактору ix padua
|
|
CN119060177A
(zh)
|
2016-05-20 |
2024-12-03 |
哈普恩治疗公司 |
单结构域血清白蛋白结合蛋白质
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
EP3515491A4
(en)
|
2016-09-21 |
2020-09-16 |
Aptevo Research and Development LLC |
CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCEDURES
|
|
US11249082B2
(en)
|
2016-10-29 |
2022-02-15 |
University Of Miami |
Zika virus assay systems
|
|
US11124577B2
(en)
|
2016-11-02 |
2021-09-21 |
Engmab Sàrl |
Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
|
|
US11535666B2
(en)
*
|
2016-12-30 |
2022-12-27 |
Cytocares (Shanghai) Inc. |
Trifunctional molecule and application thereof
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
WO2018209298A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
US11830582B2
(en)
|
2018-06-14 |
2023-11-28 |
University Of Miami |
Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
|
|
AU2019322895A1
(en)
|
2018-08-17 |
2021-03-11 |
Regeneron Pharmaceuticals, Inc. |
Method and chromatography system for determining amount and purity of a multimeric protein
|
|
MA53495A
(fr)
|
2018-08-31 |
2021-12-08 |
Regeneron Pharma |
Stratégie de dosage permettant d'atténuer le syndrome de libération de cytokines pour des anticorps bispécifiques cd3/c20
|
|
WO2020056170A1
(en)
|
2018-09-12 |
2020-03-19 |
Fred Hutchinson Cancer Research Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
CN113286817B
(zh)
|
2018-09-25 |
2025-01-28 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
WO2020097155A1
(en)
|
2018-11-06 |
2020-05-14 |
Alsatech, Inc. |
Cell-based gene therapy for neurodegenerative diseases
|
|
WO2020236792A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
EP4200332A1
(en)
|
2020-08-19 |
2023-06-28 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
US12129302B2
(en)
|
2021-08-25 |
2024-10-29 |
Ibio, Inc. |
Anti-CD-25 antibody
|